drug
paliperidone palmitate LA
Marketedupdated 3mo agoby Johnson & Johnson Innovative Medicine
Approvedcommunity read0 votes
indications
investigational
Schizophrenia
all catalysts(0)
nothing on the calendar yet
Trials studying paliperidone palmitate LA
- N/AA Bioequivalence Study of PP3M in Patients With Schizophrenia
- N/ABioequivalence Study of Long-Acting Paliperidone Palmitate in Patients With Schizophrenia
- phase3A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform
- phase4A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings
- —A Study to Analyze the Impact of Treatment With Paliperidone Palmitate on Clinical Outcomes and Hospital Resource Utilization in Adult Participants With Schizophrenia in Portugal
- —A Survey to Collect Treatment Experience Feedback From Patients, Physicians, Nurses and Carers After Switching to Paliperidone Palmitate 3-monthly
- phase4A Study to Evaluate the Ability of Conducting a Study of Oral Risperidone Followed by Paliperidone Palmitate in Rwandan Healthcare Facilities
- phase3A Study of Transition to the Paliperidone Palmitate 3-Month Formulation In Participants With Schizophrenia Previously Stabilized on the Paliperidone Palmitate 1-Month Formulation
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jan 26, 2031
~4.4 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (29)
- Nov 24, 2041method-of-use (U-3626)US 11666697
- Nov 24, 2041method-of-use (U-3626)US 11666697
- May 7, 2041method-of-use (U-3349)US 11304951
- May 7, 2041method-of-use (U-3349)US 11304951
- May 7, 2041method-of-use (U-3359)US 11324751
- May 7, 2041method-of-use (U-3359)US 11324751
- May 7, 2041method-of-use (U-3359)US 12208100
- May 7, 2041method-of-use (U-4110)US 12208100
- Sep 24, 2039method-of-use (U-3968)US 11666573
- Sep 24, 2039method-of-use (U-3968)US 11666573
- Sep 24, 2039method-of-use (U-3968)US 11666573
- Sep 24, 2039method-of-use (U-3969)US 11666573
- Sep 24, 2039method-of-use (U-3968)US 11666573
- Sep 24, 2039method-of-use (U-3968)US 11666573
- Oct 26, 2038method-of-use (U-3968)US 12128049
- Oct 26, 2038method-of-use (U-3968)US 12128049
- Oct 26, 2038method-of-use (U-3969)US 12128049
- Oct 26, 2038method-of-use (U-3968)US 12128049
- Oct 26, 2038method-of-use (U-3968)US 12128049
- Oct 26, 2038method-of-use (U-3968)US 12128049
- Apr 5, 2036method-of-use (U-2457)US 10143693
- Apr 5, 2036method-of-use (U-2458)US 10143693
- Apr 5, 2036method-of-use (U-2457)US 10143693
- Apr 5, 2036method-of-use (U-2457)US 10143693
- Jan 26, 2031method-of-use (U-2757)US 94399064.4y
- Jan 26, 2031method-of-use (U-2758)US 94399064.4y
- Jan 26, 2031method-of-use (U-2757)US 94399064.4y
- Jan 26, 2031method-of-use (U-2758)US 94399064.4y
- Jan 26, 2031method-of-use (U-2757)US 94399064.4y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 8m ago
Found something off?
comments(0)
5-min edit window · permanent after that